NEW YORK, NY / ACCESSWIRE / January 6, 2021 / Pomerantz LLP is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or the "Company") (NASDAQ:QURE). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether uniQure and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On December 21, 2020, uniQure disclosed that its hemophilia B gene therapy program, including the Company's pivotal, Phase III HOPE-B study, had been placed on clinical hold by the U.S. Food and Drug Administration ("FDA"). Specifically, uniQure advised that the FDA's "clinical hold was initiated following the submission of a safety report in mid-December relating to a possibly related serious adverse event associated with a preliminary diagnosis of hepatocellular carcinoma (HCC), a form of liver cancer, in one patient in the HOPE-B trial that was treated with etranacogene dezaparvovec (AMT-061) in October 2019."
On this news, uniQure's ordinary share price fell $7.44 per share, or 16.19%, to close at $38.51 per share on December 21, 2020.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
SOURCE: Pomerantz LLP